Core Viewpoint - A lawsuit has been filed against Compass Diversified Holdings and its executives for potential violations of federal securities laws, stemming from material misstatements in financial statements related to its subsidiary, Lugano Holdings, Inc. [1][3] Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981 [2] - Investors have until July 8, 2025, to request to be appointed to lead the case [2] Group 2: Financial Misstatements - Compass admitted that its fiscal 2022-2024 financial statements contained material misstatements regarding unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable for Lugano [3] - On June 25, 2025, Compass announced that investors should not rely on its fiscal 2022 and 2023 financial statements amid the ongoing investigation [5] Group 3: Stock Performance - Following the announcement on May 7, 2025, that investors should not rely on its fiscal 2024 financial statements, Compass's stock price plummeted approximately 62%, from $17.25 per share to $6.55 per share [4]

Core Viewpoint - Investors with significant losses in Hims & Hers Health, Inc. have the opportunity to lead a securities fraud class action lawsuit against the company [1]. Group 1: Lawsuit Details - The lawsuit alleges that between April 29, 2025, and June 23, 2025, Hims failed to disclose that it was involved in the deceptive promotion and sale of illegitimate versions of Wegovy, which posed risks to patient safety [3]. - The complaint also claims that there was a substantial risk of termination of Hims' collaboration with Novo Nordisk due to these undisclosed actions [3]. - As a result of the aforementioned issues, the positive statements made by Hims regarding its business operations and prospects were materially misleading and lacked a reasonable basis [3]. Group 2: Participation Information - Investors who suffered losses in Hims & Hers Health, Inc. are encouraged to contact the Law Offices of Howard G. Smith before August 25, 2025, to participate in the ongoing lawsuit [2]. - Interested parties can reach out via email or phone to discuss their legal rights and options regarding the class action [4].

Core Viewpoint - Investors in Rocket Pharmaceuticals, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that from February 27, 2025, to May 26, 2025, Rocket Pharmaceuticals failed to disclose significant risks, including serious adverse events (SAEs) such as participant deaths in clinical studies [3]. - The complaint states that Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to misleading positive statements about the company's operations and prospects [3]. Group 2: Participation Information - Investors who suffered losses in Rocket Pharmaceuticals are encouraged to contact the Law Offices of Howard G. Smith before August 11, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals interested in learning more about the class action or their rights can reach out to the law firm via email or phone [4][5].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Compass Group Diversified Holdings, LLC ("Compass Diversified" or the "Company") (NYSE: CODI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Compass Diversified investors who were adversely affected by alleged securities fraud between February 24, 2022 and May 7, 2025. Follow the link below to get more information and be contacted by a member of our team: https:// ...

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price following the announcement of a clinical hold by the FDA [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths during the clinical trial [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. Stock Price Impact - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share, marking a decline of approximately 37% in just one trading day [3]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for August 11, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. Law Firm Background - The Gross Law Firm, which is leading the class action, is recognized for protecting investors' rights against deceit and fraud, aiming to recover losses incurred due to misleading statements by companies [5].

AI卷起的财富风暴。 以下文章来源于AGI接口 ，作者丸都山 AGI接口 . 该诉讼已被旧金山联邦法院受理立案，包括公司CEO库克、CFO凯文·帕雷克和前任CFO均被列为 被告。 出品 | 虎嗅科技组 作者 | 丸都山 编辑 | 苗正卿 头图 | 视觉中国 在Apple Intelligence饱受争议的当下，苹果的股东们率先向这家公司开出了第一枪。 需要说明的是，在美国"企业问责制"的体系中，关于"误导性陈述"的相关指控一旦被找到证据， 几乎再无上诉成功的可能。比如英伟达在2018年被股东起诉，称黄仁勋在当年虚假地描述了加密 货币为GPU营收带来的增幅，在随后的6年中，英伟达曾多次上诉，但最终在去年被美国最高法院 驳回上诉。 回到此次事件，苹果被股东集体上诉，可能都不需要去特意地搜集证据。 因为在去年的WWDC大会上，苹果软件高级副总裁克雷格·费德里吉就曾明确表示过，"更加智能 的Siri"将在iOS 18的后续版本上推出，而直到今年iOS 26发布，这个存在于演示动画中的Siri仍然 没有看到。 就连苹果官方，现在也无法给出"Siri+Apple Intelligence"的准确时间。在今年3月，苹果在官 ...

NEW YORK, June 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid ...

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Red Cat Holdings, Inc. ("Red Cat Holdings, Inc." or the "Company") (NASDAQ: RCAT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Red Cat Holdings, Inc. investors who were adversely affected by alleged securities fraud between March 18, 2022 and January 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com ...